Having trouble accessing articles? Reset your cache.

FDA reviewing Stalevo's cardiovascular safety

FDA is reviewing the cardiovascular safety of Stalevo levodopa/carbidopa/entacapone from Orion Corp. (HSE:ORNAV; HSE:ORNBV) after a meta-analysis of 15 trials

Read the full 209 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE